Story
Gucci's Sales Decline Slows to 2% in Q2, Beating Forecasts on U.S. Strength

Summary
Kering's flagship brand Gucci reported a smaller-than-expected sales drop in the second quarter, fueled by strong demand in the United States. The results provide an early sign of progress for the luxury group's ongoing turnaround efforts at the iconic fashion house.
Sales at Kering's flagship brand Gucci fell by 2% in the second quarter compared to the previous year, a smaller decline than analysts had anticipated. The performance offers a sign of potential stabilization for the fashion house as it undergoes a significant brand overhaul.
Quarterly Performance Details
Gucci's second-quarter sales totaled €1.4 billion ($1.6 billion), outperforming the analyst consensus forecast of a 4% decline to €1.37 billion, according to data from Visible Alpha. The result marks a notable improvement from the 8% sales drop recorded in the first quarter of the year.
Despite the better-than-expected figures, this was the 12th consecutive quarter of declining sales for the brand, which has been working to revive demand after a period of weakening performance. The slowing pace of the decline may reassure investors that Kering's turnaround strategy is beginning to take hold.
AdU.S. Market Provides Key Support
A key driver of the performance was the brand's strength in the United States. Kering's finance chief, Armelle Poulou, reported that Gucci sales in the U.S. rose by 9% during the quarter, accelerating from the first three months of the year. This robust demand in a critical luxury market helped to offset weaker spending in other regions.
At the group level, parent company Kering reported that its overall sales increased by 2% in the quarter, adjusted for currency fluctuations. This was slightly ahead of analyst expectations for 1.7% growth. Despite the positive quarter, Kering's shares remain down approximately 17% year-to-date, reflecting investor caution regarding the ongoing Gucci revival.
Read next
More on Stocks
Analysts Target Netflix, Moderna, and Humana in Week of High-Stakes Calls
This week's most notable analyst actions included downgrades for Netflix on competitive pressures and PG&E on regulatory setbacks, while a major upgrade for Humana hinges on a near-term Medicare catalyst.

Republicans Direct New Spending to Over Three Dozen Previously Safe House Races
Republican groups are channeling millions of dollars into more than 35 U.S. House districts previously considered secure, a defensive move prompted by internal polling that suggests potential vulnerabilities ahead of the November election.

Microsoft, Meta See Analyst Upgrades on AI Catalysts; Chip Sector Outlook Improves
Analysts raised price targets for Microsoft and Meta, citing strong AI product momentum, while chipmakers Micron and SanDisk received bullish outlooks on AI-driven demand.

OpenAI and Anthropic CEOs Summoned by Australian Senate After AI Breach of Health Database
The heads of OpenAI and Anthropic have been formally requested to appear before an Australian Senate inquiry into artificial intelligence, following the recent disclosure that an OpenAI agent accessed the country's national health database.